“With the successful completion of the Centor sale, we have reached an important milestone. The cash inflow strengthens our financial position and supports the further reduction of our debt. In parallel with the sales, we are putting Gerresheimer back on an absolutely solid basis for the long term through the planned new capital structure,” explains Wolf Lehmann, CFO of Gerresheimer AG.
“It is particularly gratifying that we were able to complete the sale of Centor within just two months,” adds Achim Schalk, a member of the Management Board. “Our full focus is now on the carve-out of the Primary Packaging Plastics business so that we can successfully complete this transaction also as quickly as possible and implement Gerresheimer’s portfolio restructuring as planned. The new Gerresheimer will be even more focused on high-quality primary packaging and drug delivery systems. These two business areas are characterized by attractive growth prospects, high regulatory barriers to entry, and long-term customer relationships.”
With the cash inflow from the now-completed sale of Centor and the expected cash inflow from the sale of the Primary Packaging Plastics business, Gerresheimer will significantly reduce its debt. Following the completion of the Primary Packaging Plastics sale, a comprehensive refinancing of the Group is also planned, which is currently being prepared in consultation with the creditors.
About Gerresheimer
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of primary packaging solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes infusion, dropper and syrup bottles, tablet containers, vials, syringes, pens, auto-injectors, inhalers, ampoules, cartridges, on-body devices as well as digital solutions for therapy support. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With 39 production sites in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. The Group generated revenues of around EUR 2.3bn in 2025 and employs over 13,000 people. Gerresheimer AG is listed on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).
Contact Gerresheimer
